CGTX
Cognition Therapeutics, Inc.
Price Chart
Latest Quote
$1.45
+0.03 (+2.11%)
Current Price
| Previous Close | $1.42 |
| Open | $1.50 |
| Day High | $1.50 |
| Day Low | $1.39 |
| Volume | 1,271,134 |
Stock Information
| Shares Outstanding | 89.50M |
| Total Debt | $638K |
| Cash Equivalents | $36.81M |
| Net Income | $-19.58M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $129.77M |
| EPS (TTM) | $-0.23 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $76.41M |
| Income | $-19.58M |
| Book/sh | $0.39 |
| Cash/sh | $0.41 |
| Employees | 14 |
Financial Ratios
| Debt/Eq | 1.86 |
Returns & Margins
Ownership
| Insider Ownership | 2.25% |
| Institutional Ownership | 23.49% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.24 |
| P/B | 3.77 |
Analyst Data
| Recommendation | none |
| Target Price | $3.50 |
Technical Indicators
| SMA20 | $1.26 |
| SMA50 | $1.20 |
| SMA200 | $1.38 |
| RSI | 66.27 |
| ATR | 0.1344 |
| Shares Float | 81.85M |
| Short Float | 7.78% |
| Short Ratio | 7.80 |
| Volatility | 1.75 |
| Rel Volume | 1.10 |
Performance History
| Week | +20.83% |
| Month | +30.63% |
| Quarter | +34.26% |
| 6 Months | -4.61% |
| YTD | -1.36% |
| Year | +417.86% |
| 3 Years | -50.00% |
| 10 Years | -88.65% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.45 | 1,303,600 |
| 2026-06-17 | $1.42 | 2,358,600 |
| 2026-06-16 | $1.26 | 1,078,600 |
| 2026-06-15 | $1.21 | 857,800 |
| 2026-06-12 | $1.21 | 463,000 |
| 2026-06-11 | $1.20 | 604,300 |
| 2026-06-10 | $1.14 | 489,200 |
| 2026-06-09 | $1.15 | 692,000 |
| 2026-06-08 | $1.21 | 826,000 |
| 2026-06-05 | $1.29 | 1,149,800 |
| 2026-06-04 | $1.36 | 1,821,900 |
| 2026-06-03 | $1.42 | 2,211,300 |
| 2026-06-02 | $1.35 | 2,901,700 |
| 2026-06-01 | $1.25 | 2,477,500 |
| 2026-05-29 | $1.18 | 680,100 |
| 2026-05-28 | $1.19 | 635,000 |
| 2026-05-27 | $1.19 | 798,200 |
| 2026-05-26 | $1.24 | 835,700 |
| 2026-05-22 | $1.26 | 528,900 |
| 2026-05-21 | $1.25 | 906,700 |
| 2026-05-20 | $1.29 | 1,628,100 |
| 2026-05-19 | $1.11 | 560,900 |
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
đ° Latest News
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?
Insider Monkey âĸ 2026-06-02T13:56:29Z
Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs
Exec Edge âĸ 2026-05-12T12:35:06Z
NanoViricides to Participate at D. Boral Capital Global Conference in NYC
Exec Edge âĸ 2026-05-07T12:35:07Z
NanoViricidesâ Measles Treatment Granted Orphan Drug Designation by FDA
Exec Edge âĸ 2026-05-06T12:35:33Z
Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans
MarketBeat âĸ 2026-04-13T20:35:29Z
Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ...
GuruFocus.com âĸ 2026-03-26T19:02:18ZCognition Therapeutics Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-26T14:07:15Z
Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely?
Simply Wall St. âĸ 2025-12-05T14:46:02Z
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
Zacks âĸ 2025-10-27T13:40:02Z
Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade
Zacks âĸ 2025-10-08T16:00:05Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $13,000 | $25,000 | $27,000 | $28,000 |
| Total Expenses | $24,393,000 | $34,417,000 | $25,919,000 | $21,334,000 |
| Other Income Expense | $919,000 | $471,000 | $158,000 | $-35,000 |
| Other Non Operating Income Expenses | $919,000 | $666,000 | $158,000 | $-35,000 |
| Net Non Operating Interest Income Expense | $-13,000 | $-25,000 | $-27,000 | $-28,000 |
| Interest Expense Non Operating | $13,000 | $25,000 | $27,000 | $28,000 |
| Operating Expense | $24,393,000 | $34,417,000 | $25,919,000 | $21,334,000 |
| Other Operating Expenses | $-23,406,000 | $-19,549,000 | $-24,805,000 | $-22,217,000 |
| General And Administrative Expense | $10,612,000 | $12,290,000 | $13,528,000 | $13,227,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-23,487,000 | $-33,971,000 | $-25,788,000 | $-21,397,000 |
| Net Interest Income | $-13,000 | $-25,000 | $-27,000 | $-28,000 |
| Normalized Income | $-23,487,000 | $-33,776,000 | $-25,788,000 | $-21,397,000 |
| Net Income From Continuing And Discontinued Operation | $-23,487,000 | $-33,971,000 | $-25,788,000 | $-21,397,000 |
| Total Operating Income As Reported | $-47,799,000 | $-53,966,000 | $-50,724,000 | $-43,551,000 |
| Net Income Common Stockholders | $-23,487,000 | $-33,971,000 | $-25,788,000 | $-21,397,000 |
| Net Income | $-23,487,000 | $-33,971,000 | $-25,788,000 | $-21,397,000 |
| Net Income Including Noncontrolling Interests | $-23,487,000 | $-33,971,000 | $-25,788,000 | $-21,397,000 |
| Net Income Continuous Operations | $-23,487,000 | $-33,971,000 | $-25,788,000 | $-21,397,000 |
| Pretax Income | $-23,487,000 | $-33,971,000 | $-25,788,000 | $-21,397,000 |
| Special Income Charges | $0 | $-195,000 | $0 | $0 |
| Operating Income | $-24,393,000 | $-34,417,000 | $-25,919,000 | $-21,334,000 |
| Per Share | ||||
| Diluted EPS | $-0.32 | $-0.86 | $-0.86 | $-0.91 |
| Basic EPS | $-0.32 | $-0.86 | $-0.86 | $-0.91 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-23,246,000 | $-33,485,000 | $-25,509,000 | $-21,134,000 |
| Total Unusual Items | $0 | $-195,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $-195,000 | $0 | $0 |
| Reconciled Depreciation | $228,000 | $266,000 | $252,000 | $235,000 |
| EBITDA (Bullshit earnings) | $-23,246,000 | $-33,680,000 | $-25,509,000 | $-21,134,000 |
| EBIT | $-23,474,000 | $-33,946,000 | $-25,761,000 | $-21,369,000 |
| Diluted Average Shares | $72,766,983 | $39,730,148 | $30,029,087 | $23,640,199 |
| Basic Average Shares | $72,766,983 | $39,730,148 | $30,029,087 | $23,640,199 |
| Diluted NI Availto Com Stockholders | $-23,487,000 | $-33,971,000 | $-25,788,000 | $-21,397,000 |
| Gain On Sale Of Business | $0 | $-195,000 | $0 | - |
| Research And Development | $37,187,000 | $41,676,000 | $37,196,000 | $30,324,000 |
| Selling General And Administration | $10,612,000 | $12,290,000 | $13,528,000 | $13,227,000 |
| Other Gand A | $10,612,000 | $12,290,000 | $13,528,000 | $13,227,000 |
| Preferred Stock Dividends | - | - | - | - |
| Other Special Charges | - | - | - | - |
| Gain On Sale Of Security | - | - | - | - |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $34,271,000 | $18,750,000 | $24,474,000 | $40,249,000 |
| Total Assets | $48,390,000 | $30,234,000 | $35,163,000 | $50,425,000 |
| Total Non Current Assets | $399,000 | $679,000 | $941,000 | $2,778,000 |
| Current Assets | $47,991,000 | $29,555,000 | $34,222,000 | $47,647,000 |
| Other Current Assets | $1,068,000 | $1,860,000 | $3,019,000 | $2,413,000 |
| Restricted Cash | $190,000 | $0 | - | - |
| Receivables | $9,923,000 | $2,686,000 | $1,281,000 | $3,672,000 |
| Other Receivables | $9,923,000 | $2,686,000 | $1,281,000 | $3,672,000 |
| Cash Cash Equivalents And Short Term Investments | $36,810,000 | $25,009,000 | $29,922,000 | $41,562,000 |
| Cash And Cash Equivalents | $36,810,000 | $25,009,000 | $29,922,000 | $41,562,000 |
| Other Non Current Assets | - | - | - | $1,732,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $638,000 | $814,000 | $1,238,000 | $1,478,000 |
| Long Term Debt And Capital Lease Obligation | $195,000 | $342,000 | $520,000 | $695,000 |
| Current Debt And Capital Lease Obligation | $443,000 | $472,000 | $718,000 | $783,000 |
| Current Debt | $307,000 | $279,000 | $544,000 | $634,000 |
| Other Current Borrowings | $307,000 | $279,000 | $544,000 | $634,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $14,119,000 | $11,484,000 | $10,689,000 | $10,176,000 |
| Total Non Current Liabilities Net Minority Interest | $195,000 | $342,000 | $520,000 | $2,381,000 |
| Current Liabilities | $13,924,000 | $11,142,000 | $10,169,000 | $7,795,000 |
| Current Deferred Liabilities | $367,000 | $1,066,000 | $1,701,000 | $1,702,000 |
| Payables And Accrued Expenses | $11,545,000 | $8,078,000 | $6,585,000 | $4,440,000 |
| Payables | $1,119,000 | $1,984,000 | $3,695,000 | $3,216,000 |
| Accounts Payable | $1,119,000 | $1,984,000 | $3,695,000 | $3,216,000 |
| Non Current Deferred Liabilities | - | - | $0 | $1,686,000 |
| Derivative Product Liabilities | - | - | - | - |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $34,271,000 | $18,750,000 | $24,474,000 | $40,249,000 |
| Total Equity Gross Minority Interest | $34,271,000 | $18,750,000 | $24,474,000 | $40,249,000 |
| Stockholders Equity | $34,271,000 | $18,750,000 | $24,474,000 | $40,249,000 |
| Retained Earnings | $-198,647,000 | $-175,160,000 | $-141,189,000 | $-115,401,000 |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $-195,000 | $-199,000 |
| Other Equity Adjustments | - | - | $-195,000 | $-199,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $88,904,161 | $59,854,877 | $32,165,478 | $28,991,548 |
| Share Issued | $88,904,161 | $59,854,877 | $32,165,478 | $28,991,548 |
| Tangible Book Value | $34,271,000 | $18,750,000 | $24,474,000 | $40,249,000 |
| Invested Capital | $34,578,000 | $19,029,000 | $25,018,000 | $40,883,000 |
| Working Capital | $34,067,000 | $18,413,000 | $24,053,000 | $39,852,000 |
| Capital Lease Obligations | $331,000 | $535,000 | $694,000 | $844,000 |
| Total Capitalization | $34,271,000 | $18,750,000 | $24,474,000 | $40,249,000 |
| Additional Paid In Capital | $232,828,000 | $193,850,000 | $165,826,000 | $155,820,000 |
| Capital Stock | $90,000 | $60,000 | $32,000 | $29,000 |
| Common Stock | $90,000 | $60,000 | $32,000 | $29,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $195,000 | $342,000 | $520,000 | $695,000 |
| Current Deferred Revenue | $367,000 | $1,066,000 | $1,701,000 | $1,702,000 |
| Current Capital Lease Obligation | $136,000 | $193,000 | $174,000 | $149,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,569,000 | $1,526,000 | $1,165,000 | $870,000 |
| Current Accrued Expenses | $10,426,000 | $6,094,000 | $2,890,000 | $1,224,000 |
| Net PPE | $399,000 | $679,000 | $941,000 | $1,046,000 |
| Accumulated Depreciation | $-187,000 | $-1,156,000 | $-1,049,000 | $-953,000 |
| Gross PPE | $586,000 | $1,835,000 | $1,990,000 | $1,999,000 |
| Other Properties | $142,000 | $1,197,000 | $1,193,000 | $1,057,000 |
| Machinery Furniture Equipment | $138,000 | $140,000 | $140,000 | $129,000 |
| Buildings And Improvements | $306,000 | $498,000 | $657,000 | $813,000 |
| Properties | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | - | - | $0 | $1,686,000 |
| Non Current Accrued Expenses | - | - | - | - |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-24,588,000 | $-28,478,000 | $-16,165,000 | $-18,704,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-24,588,000 | $-28,474,000 | $-16,018,000 | $-18,533,000 |
| Cash Flow From Continuing Operating Activities | $-24,588,000 | $-28,474,000 | $-16,018,000 | $-18,533,000 |
| Operating Gains Losses | $41,000 | $195,000 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $9,000 | $-4,000 | $-147,000 | $-171,000 |
| Cash Flow From Continuing Investing Activities | $9,000 | $-4,000 | $-147,000 | $-171,000 |
| Capital Expenditure | - | $-4,000 | $-147,000 | $-171,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $37,016,000 | $24,350,000 | $5,332,000 | $5,324,000 |
| Financing Cash Flow | $36,570,000 | $23,565,000 | $4,521,000 | $5,546,000 |
| Cash Flow From Continuing Financing Activities | $36,570,000 | $23,565,000 | $4,521,000 | $5,546,000 |
| Net Other Financing Charges | $-164,000 | $-128,000 | - | - |
| Net Common Stock Issuance | $37,016,000 | $24,350,000 | $5,332,000 | $5,324,000 |
| Common Stock Issuance | $37,016,000 | $24,350,000 | $5,332,000 | $5,324,000 |
| Other | ||||
| Repayment Of Debt | $-353,000 | $-739,000 | $-811,000 | $-1,396,000 |
| End Cash Position | $37,000,000 | $25,009,000 | $29,922,000 | $41,562,000 |
| Beginning Cash Position | $25,009,000 | $29,922,000 | $41,562,000 | $54,721,000 |
| Changes In Cash | $11,991,000 | $-4,913,000 | $-11,644,000 | $-13,158,000 |
| Proceeds From Stock Option Exercised | $71,000 | $82,000 | $0 | $1,618,000 |
| Net Issuance Payments Of Debt | $-353,000 | $-739,000 | $-811,000 | $-1,396,000 |
| Net Long Term Debt Issuance | $-353,000 | $-739,000 | $-811,000 | $-1,396,000 |
| Long Term Debt Payments | $-353,000 | $-739,000 | $-811,000 | $-1,396,000 |
| Net PPE Purchase And Sale | $9,000 | $-4,000 | $-147,000 | $-171,000 |
| Sale Of PPE | $9,000 | $0 | - | - |
| Purchase Of PPE | $0 | $-4,000 | $-147,000 | $-171,000 |
| Change In Working Capital | $-3,457,000 | $1,288,000 | $4,846,000 | $-943,000 |
| Change In Other Working Capital | $-699,000 | $-635,000 | $-1,687,000 | $2,635,000 |
| Change In Other Current Liabilities | $-204,000 | $-159,000 | $-150,000 | $-121,000 |
| Change In Payables And Accrued Expense | $3,510,000 | $1,854,000 | $2,440,000 | $-749,000 |
| Change In Prepaid Assets | $1,173,000 | $1,633,000 | $1,852,000 | $-1,302,000 |
| Change In Receivables | $-7,237,000 | $-1,405,000 | $2,391,000 | $-1,406,000 |
| Stock Based Compensation | $2,087,000 | $3,748,000 | $4,354,000 | $3,572,000 |
| Depreciation Amortization Depletion | $228,000 | $266,000 | $252,000 | $235,000 |
| Depreciation And Amortization | $228,000 | $266,000 | $252,000 | $235,000 |
| Depreciation | $228,000 | $266,000 | $252,000 | $235,000 |
| Net Foreign Currency Exchange Gain Loss | $0 | $195,000 | $0 | - |
| Gain Loss On Sale Of PPE | $41,000 | $0 | - | - |
| Net Income From Continuing Operations | $-23,487,000 | $-33,971,000 | $-25,788,000 | $-21,397,000 |
| Effect Of Exchange Rate Changes | - | $0 | $4,000 | $-1,000 |
| Other Non Cash Items | - | - | $318,000 | - |
| Change In Other Current Assets | - | - | - | $-1,732,000 |
| Change In Accrued Expense | - | - | - | $343,000 |
| Change In Payable | - | - | - | $-1,092,000 |
| Change In Account Payable | - | - | - | $-1,092,000 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-14